What is the gross-to-net bubble and why does it matter?

The gross-to-net (GTN) bubble refers to the growing gap between a drugs list price (WAC) and the actual net price received by manufacturers after rebates, discounts, chargebacks, and fees. The average GTN discount across branded drugs now exceeds 50%. This matters because it obscures real pricing trends and creates misaligned incentives throughout the supply chain.